{'fraction_non_alphanumeric': 0.021352313167259787, 'fraction_numerical': 0.0, 'mean_word_length': 6.1525423728813555, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
The potential utility of melatonin in the treatment of childhood cancer

Childhood cancer management has improved considerably, with the overall objective of preventing early‐life cancers completely. However, cancer remains a major cause of death in children, with the survivors developing anticancer treatment‐specific health problems. Therefore, the anticancer treatment needs further improvement. Melatonin is a effective antioxidant and circadian pacemaker. Through multiple mechanisms, melatonin has significant positive effects on multitude adult cancers by increasing survival and treatment response rates, and slowing disease progression. In addition, melatonin appears to be safe for children. As an appealing therapeutic agent, we herein address several key concerns regarding melatonin's potential for treating children with cancer.